Table 3.

Effects of anti-hyperglycemic drugs on metabolic dysfunction-associated steatotic liver disease^55,56,62

	Liver parameters					Cardiorenal-metabolic parameters
	Serum aminotransferase	Liver fat	Liver fibrosis	MASH resolution		Body weight	Cardiorenal benefits
Pioglitazone	↓	↓	↓	Yes		↑	↔
GLP1 RAs	↓	↓	↓	Yes		↓	Yes
GLP1/GIP RAs	↓	↓	Unknown	Unknown		↓	Unknown
SGLT2 inhibitors	↓	↓	Unknown	Unknown		↓	Yes
Insulin	↓	↓	Unknown	Unknown		↑	↔
Metformin	↔	↔	↔	↔		↔	↔
DPP-4 inhibitors	↔	↔	↔	↔		↔	↔

MASH, metabolic dysfunction-associated steatohepatitis; GLP1 RA, glucagon-like peptide-1 receptor agonist; GIP RA, glucose-dependent insulinotropic polypeptide receptor agonist; SGLT2, sodium glucose co-transporter-2; DPP-4, dipeptidyl peptidase-4.